Abstract 672P
Background
CDK8 and its paralog CDK19 are part of the mediator complex connecting enhancers and core promoters and regulating genes responsible for oncogenic transformation and differentiation. RVU120 is a selective CDK8/19 inhibitor, currently in phase 1 clinical development. RVU120 showed strong anticancer activity in non-clinical cancer models.
Methods
In the ongoing phase I/II study (NCT05052255), patients with metastatic or locally advanced solid tumors receive RVU120 until disease progression or unacceptable toxicity. Primary objectives are safety, tolerability, and determination of the recommended phase 2 dose. Secondary objectives include ORR, pharmacokinetic and pharmacodynamics. Molecular response to RVU120 is assessed by genetic profiling of tumor biopsies and ctDNA. NanoString technology is used for transcriptional profiling of tumor biopsies.
Results
As of 01 May 2023, there were 30 patients treated across 7 cohorts (75 - 375 mg). The most frequent AEs were nausea and vomiting, all were G1 or 2. No patient experienced a DLT, 10 SAEs were reported in 6 patients (worsening of tumoral pain, urinary tract infection, medullary compression, lower GI bleeding, worsening of basal ataxia/dizziness, renal calculi, stroke). One patient died following an SAE of general physical health deterioration due to PD. No SAE was considered IMP related. A total of 15 patients had at least 1 RECIST assessment: 2 PD (21% and 26% increase in TL size), 13 radiologic SD (between -4% and +11% change in TL size). Out of these, a patient with refractory pancreatic cancer achieved a reduction of CA19.9 on 3 consecutive time points and radiologic SD after cycle 3. Pharmacodynamic profiling of all patients revealed target engagement of >70% at doses up to 375 mg. Data from genetic and transcriptomic profiling will be presented.
Conclusions
After 7 dose levels with single agent RVU120 (up to 375 mg), a favorable safety profile was observed. Most TEAEs were mild/moderate, no DLTs nor IMP related SAEs were reported. RECIST assessments of 15 patients demonstrated radiologic SD in 13 patients. Dose escalation is currently ongoing with PK modeling indicating high target engagement.
Clinical trial identification
NCT05052255.
Editorial acknowledgement
Legal entity responsible for the study
Ryvu Therapeutics SA.
Funding
Ryvu Therapeutics SA.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
679P - Lurbinectedin (LRB) pharmacokinetics (PK) and safety when co-administered with itraconazole (ITZ) in patients with advanced solid tumor
Presenter: Irene Moreno
Session: Poster session 17
680P - First results from the phase I trial of the ATR inhibitor, ART0380, in advanced solid tumors
Presenter: Kathleen Moore
Session: Poster session 17
681P - First-in-human study of ATR inhibitor IMP9064 monotherapy and in combination with PARP inhibitor senaparib in patients with advanced solid tumors
Presenter: Chia-Chi Lin
Session: Poster session 17
683P - Preclinical evaluation of HLX42, a novel EGFR-targeting ADC, for cetuximab or TKI resistant cancer
Presenter: Yongqiang Shan
Session: Poster session 17
684P - Phase I trial of SHR-A1811 in HER2-expressing advanced gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJ) and colorectal cancer (CRC)
Presenter: Jin Li
Session: Poster session 17
685P - BL-M07D1, a HER2 antibody-drug conjugate in subjects with locally advanced or metastatic HER2 expressing breast cancer and other solid tumors
Presenter: Erwei Song
Session: Poster session 17
686P - Phase I study of HRS8807, an oral selective ER covalent antagonist (SERCA), in ER+/HER2- locally advanced (LA) or metastatic (M) breast cancer (BC)
Presenter: Jiong Wu
Session: Poster session 17
687P - A CRUK phase I/IIA, first in human dose-escalation and expansion trial of HMBD-001 (an anti-HER3 antibody) in patients with advanced HER3 positive solid tumours
Presenter: Johann de Bono
Session: Poster session 17
688P - Pharmacokinetics of HMBD-001, a human monoclonal antibody targeting HER3, a CRUK first-in-human phase I trial in patients with advanced solid tumours
Presenter: Oladipo Idowu
Session: Poster session 17
689P - DB-1305 (a Trop-2 targeted antibody-drug-conjugate [ADC]) in patients (pts) with advanced solid tumors: Preliminary clinical results from the phase (Ph) I/IIa study
Presenter: Omkar Marathe
Session: Poster session 17